FTC Continues to Call out Drug and Device Manufacturers for Improper Orange Book Listings
- May 23, 2025
The Federal Trade Commission (FTC) is renewing its challenge to more than 200 patents across 17 brand-name products as improperly listed in the Food and Drug Administration’s (FDA’s) Orange Book.
ARTICLE TAGS
You must be logged in to access this content.